DBP International AB has together with Bio Vitos Medical Ltd signed an agreement on scientific, technical and sales collaboration with Belarusian Academpharm

Double Bond Pharmaceutical International AB (publ) (“DBP”) has signed a 3-way agreement with Bio Vitos Medical Ltd (“Bio Vitos”) and Academpharm (Republic of Belarus) concerning a technical and scientific collaboration.

The purpose of the agreement between Academpharm and Bio Vitos is to get access to its products on the markets in the Eurasian Economic Union (EaEU). Bio Vitos has a line of more than 40 Omega 3 products from North Norway, containing vitamins, minerals, iron succinate etc.

The Bio Vitos agreement with Academpharm, gives access to the countries: Belarus, Russia, Kazakhstan, Turkmenistan, Azerbaijan, and Armenia, a total of markets with almost 200 million inhabitants.

As previously announced, DBP owns 20 % of Bio Vitos:  https://mb.cision.com/Main/12720/3440256/1486281.pdf

About BioVitos: BioVitos is an English limited company, specializing in development and sale of dietary supplements, based on high quality Omega 3 salmon oil from North Norway.

Bio Vitos also has Omega 3 products added with cannabis oil (CBD).

Bio Vitos is in preparation for an application to be part of the Danish Medical Agency's pilot program for medical cannabis.

29.39 % of Bio Vitos is owned by Craven House Capital Plc ("CRV") which is listed on the London Stock Exchange's AIM list.

About Academpharm: Academpharm is a dynamically developing high-tech state-owned pharmaceutical company for production and distribution of high-quality drug substances and biologically active additives.

Belarus State Academpharm is focused on the pharmaceutical industry within the Eurasian Economic Union (EaEU), the European Union (EU) and the US market. https://academpharm.by/en/